Adjusted EBITDA1 for the fourth quarter of 2025 increased 53% to $2.3 million, compared with $1.5 million for the fourth quarter of 2024. Net income for the fourth quarter of 2025 increased 90% to ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results